Scythian Biosciences (TSXV:SCYB) has made its first strategic purchase, the company announced on Monday (July 30). following the sale of its Latin American assets to a major Canadian cannabis licensed producer (LP). The company also revealed a listing change for its stock.

On July 17 Scythian announced a transaction with Aphria (TSX:APH) for all of its interests across the Latin American cannabis market for a price tag of C$193 million in Aphria shares paid to Scythian.


The TSX Venture-listed (TSXV) cannabis company is now eyeing an entry into the Florida market with the purchase of CannCure Investments, a Canadian company currently working on the acquisition of a stake in 3 Boys Farms, a licensed producer in the state.

Rob Reid, Scythian’s CEO, said Florida is becoming one of the “largest and fastest growing medical cannabis markets” in the US.

The prized acquisition of 3 Boys Farms includes its 40,000 square feet of greenhouses for cannabis cultivation and its licenses for retail shops. According to Scythian, the Florida producer is in the process of securing locations across the state.

Scythian drops TSXV to pursue US asset

Due to the potential entry of the US cannabis market, Scythian revealed to investors it will stop offering its stock on the TSXV and will now list on the Canadian Securities Exchange (CSE), an exchange that allows listings to hold assets in the federally illegal market.

The company told investors it expects the exchange transition will be done within the next 10 business days. Currently Scythian’s share trading is halted.

The entire deal, which also includes the acquisition of an undisclosed medical healthcare organization in Florida, consist of a package payment Scythian will initially purchase a 70 percent stake in CannCure and obtain the option for the remaining 30 percent at the same valuation.

According to the company the transaction consists of a C$93.3 million in equity from Scythian common shares, with the addition of a C$43.2 million cash investment into the company.

In order for the Scythian-CannCure transaction to complete, the investment company must close its initial 60 percent stake acquisition of 3 Boys Farms before August 31.

Scythian is also requiring CannCure to hold an option to acquire the balance of the issued and outstanding shares before the end of 2018.

Investor takeaway

Following the dump of its Latin American assets to Aphria, Scythian has elected to seek a stake in the US market which will lead it to swap public exchanges.

Florida has proved to be a worthwhile market for public cannabis operators and a tentative upcoming vote on the legalization of cannabis for adult-use could provide an even higher boost to the assets in the state.

The last available share price for Scythian was C$3.49 on July 25.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less